INVO Fertility Inc Dossier
Qualitative Analysis
Business overview
INVO Fertility, Inc. (formerly known as NAYA Biosciences, Inc. and previously INVO Bioscience, Inc.) is a healthcare services and technology company focused on expanding access to advanced assisted reproductive technology (ART). The company operates a growing network of fertility clinics in the United States, including the Wisconsin Fertility Institute, Atlanta Clinic, and the newly acquired Family Beginnings clinic in Indiana. INVO Fertility is also the developer and distributor of the INVOcell intravaginal culture (IVC) device, a proprietary, FDA-cleared medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. This procedure offers a more natural, intimate, and cost-effective alternative to traditional in vitro fertilization (IVF).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Pivoting the business model from primarily distributing the INVOcell medical device to establishing, acquiring, and operating physical fertility clinics and INVO Centers across the United States.
Expected impact: Aims to capture higher-margin clinical service revenues and build a scalable, recurring revenue model.
Aligning owned clinics with leading fertility benefits managers and networks to broaden access to employer-sponsored patients.
Expected impact: Expands the addressable patient market, improves the payor mix, and drives organic patient volume growth.
Investing in advanced clinical technologies, such as time-lapse incubation technology at the Wisconsin Fertility Institute and AI-powered scribe platforms (Heidi Health).
Expected impact: Enhances embryo monitoring, supports clinical decision-making, improves workflow efficiency, and elevates patient engagement.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To expand INVO's clinical footprint into Indiana and the broader Midwest, adding an established, profitable clinic that was an early adopter of the INVOcell solution.
Financial impact: Adds profitable scale, with the clinic having generated approximately $1.2 million in revenue and $0.2 million in net income for the trailing twelve months ended September 30, 2025.
Strategic Partnerships
High; provides in-network access to WFI for Progyny's 7.2 million covered lives, significantly expanding the clinic's addressable market and improving payor mix.
Terms: Standard in-network provider reimbursement terms
Medium; integrates an innovative AI-powered scribe platform into clinic workflows to enhance operational efficiency.
Terms: Not disclosed